OBJECTIVE. Monoclonal antibodies that target the programmed cell death 1 (PD-1) immune checkpoint protein and its associated ligands, PD-L1 and PD-L2, and targeted inhibitors of mutated signal transduction molecules such as BRAF inhibitors show immense promise in treating patients with melanoma. We discuss the use of 18F-FDG PET/CT for assessing therapy effectiveness, staging advanced disease, and determining prognosis of patients with melanoma. CONCLUSION. FDG PET/CT is useful in staging disease, assessing therapy, and determining prognosis in patients with melanoma.
- FDG PET/CT
- Immune modulation therapy
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging